Independent validation of prognostic value of 22 microRNAs (miRs) in stage I-II lung adenocarcinoma (AC)

M. Skrzypski, K. Goryca, A. Szymanowska-Narloch, E. Jassem, P. Czapiewski, W. Biernat, R. Pawlowski, W. Rzyman, J. Jassem (Warsaw, Poland)

Source: Annual Congress 2012 - New mechanisms in non-neoplastic and neoplastic lung diseases
Session: New mechanisms in non-neoplastic and neoplastic lung diseases
Session type: Oral Presentation
Number: 1404
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Skrzypski, K. Goryca, A. Szymanowska-Narloch, E. Jassem, P. Czapiewski, W. Biernat, R. Pawlowski, W. Rzyman, J. Jassem (Warsaw, Poland). Independent validation of prognostic value of 22 microRNAs (miRs) in stage I-II lung adenocarcinoma (AC). Eur Respir J 2012; 40: Suppl. 56, 1404

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Independent prognostic und predictive value of blood vessel invasion (BVI) in curatively (R0) resected stage II and IIIA non-small cell lung (NSCLC) cancer patients
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012

The risk of distant metastases and prognosis prediction in early stage squamous cell lung cancer (SqCLC) by means of 3 microRNAs expression assessment
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011


LATE-BREAKING ABSTRACT: Prognostic value of microRNAs expression in stage I-IIIA lung adenocarcinoma (AC)
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013

Expression of D2-40 in small cell lung carcinomas (SCLC); Association with lymphatic invasion(L.I), clinical parameters and prognosis
Source: Annual Congress 2010 - New mechanisms and markers in human lung cancer
Year: 2010

A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP)
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003

FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results
Year: 2011


Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Actual challenges in thoracic surgery
Year: 2010

LATE-BREAKING ABSTRACT: A mRNA signature predicts outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V): A ELCWP prospective study
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012


C-kit (CD 117): a new prognostic factor in small cell lung cancer (SCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 478s
Year: 2001

Quantitative RT-PCR 3-gene expression signature predicts survival in early-stage non-small cell lung cancer (NSCLC) patients (pts)
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008


Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC)
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 269s
Year: 2002

Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)?
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002

Prognostic value of microRNAs profiling in early stage squamous cell lung cancer
Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer
Year: 2009

Prognostic value of three-microRNA expression profile in early stage squamous cell lung cancer (SqCLC)
Source: Annual Congress 2010 - New mechanisms and markers in human lung cancer
Year: 2010

Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE)
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001

Carbonic anhydrase 9 expression (CA9e) profile combined with growth patterns (GPs) in non-small cell lung cancer (NSCLC) identifies a group of patients with an extremely poor prognosis
Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Year: 2005


Biological role of prognostic microRNAs (miRNAs) in squamous lung carcinoma (SCC) cells
Source: International Congress 2015 – Latest news on miRNAs in pulmonary research
Year: 2015


Validation and comparison of several published prognostic systems for patients with small cell lung cancer
Source: Eur Respir J 2011; 38: 657-663
Year: 2011



Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019